Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.
about
Interplay between sirtuins, MYC and hypoxia-inducible factor in cancer-associated metabolic reprogrammingPhotoacoustic monitoring of tumor and normal tissue response to radiationCellular and molecular mechanisms underlying oxygen-dependent radiosensitivityOptical imaging of tumor hypoxia dynamics.Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy responseEffects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells.Targeting MYC Dependence by Metabolic Inhibitors in CancerHypoxia-specific targets in cancer therapy: role of splice variantsLongitudinal optical imaging of tumor metabolism and hemodynamicsMagnetic resonance imaging of the tumor microenvironment in radiotherapy: perfusion, hypoxia, and metabolism.Global gene expression profiling in three tumor cell lines subjected to experimental cycling and chronic hypoxia.Spectral imaging reveals microvessel physiology and function from anastomoses to thromboses.Intermittent hypoxia effect on osteoclastogenesis stimulated by neuroblastoma cells.Intermittent hypoxia regulates stem-like characteristics and differentiation of neuroblastoma cells.A generic cycling hypoxia-derived prognostic gene signature: application to breast cancer profiling.Beclin-1-independent autophagy positively regulates internal ribosomal entry site-dependent translation of hypoxia-inducible factor 1α under nutrient deprivation.Imaging cycling tumor hypoxia.Cycling hypoxia induces a specific amplified inflammatory phenotype in endothelial cells and enhances tumor-promoting inflammation in vivoIntermittent hypoxia selects for genotypes and phenotypes that increase survival, invasion, and therapy resistanceRole of compartmentalization on HiF-1α degradation dynamics during changing oxygen conditions: a computational approach.Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels.Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis.The In Vitro and In Vivo Activity of the Microtubule Disruptor STX140 Is Mediated by Hif-1 Alpha and CAIX ExpressionBiological characteristics of intratumoral [F-18]‑fluoromisonidazole distribution in a rodent model of glioma.Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies.Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis.Collagen prolyl hydroxylases are essential for breast cancer metastasis.HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferationMeasuring tumor cycling hypoxia and angiogenesis using a side-firing fiber optic probe.Biologically conformal treatment: biomarkers and functional imaging in radiation oncology.Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cellsMetabolic transformation in cancer.Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.Novel imaging provides new insights into mechanisms of oxygen transport in tumors.Rethinking the Warburg effect with Myc micromanaging glutamine metabolism.Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases.Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory diseaseAutophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation.Obstructive sleep apnea and cancer: effects of intermittent hypoxia?
P2860
Q26991931-22E1FA08-0029-4E69-9053-93D04B7CE86CQ27348776-D3C723F4-3C65-4533-A8F5-68067A065B7DQ28087499-F506AB08-5224-43B4-AB12-C39CBE5EFF0EQ30429244-2316D1DC-602C-4478-B8C9-52465A07D0BDQ30573416-C9A8C0DA-3185-40DA-88DB-FA7A3B5B6249Q30838633-4174D2E1-1F0B-4750-9E0A-DC8B3B69C794Q33608493-FEA32E08-95DD-4ECB-A3CF-5DC3293D7E1CQ33630837-26DB27C8-0F60-4108-A308-C8D22DCF7DB7Q33632108-089412C1-3D97-4742-8739-04B7A3284D40Q33764933-ACEF476D-7AC0-4D65-973F-30169B9A43F6Q34047326-E5A3B1AC-0BC2-4FA6-AC93-DEE6AD77E685Q34049847-51D42A4E-DBA1-40F5-9E51-BEBEA02717ABQ34078699-30D84454-5442-4D3C-9FB4-1F61C2548EEFQ34170335-0FE1C945-9392-4688-84F6-F7DAEADF85E4Q34334455-7A2EC841-AF5B-4783-B733-D25AE486FEAAQ34365765-E5DC5D32-54D1-4AEF-81C5-D229766A5639Q34686519-AA2AB908-A0A0-4A61-9C71-49D29CFFED80Q35024044-362500FA-7394-4C98-85BD-96B03E741DF0Q35219886-286195D5-8511-405C-9ED5-0D38A0DB8D51Q35358870-72D78847-CFA0-4784-AD21-00A19A0892A1Q35916654-BDB4A7F7-E358-4922-8870-91637AB933EEQ36047741-54BB3762-5D2D-441B-A67A-EDF9DB0F92A5Q36107356-3219A251-B05F-4AF0-8BB0-B558B6A3BE5AQ36134768-1AC6CED9-9507-4732-A01D-BFB336EDCAC1Q36684412-F039FF68-5950-44F3-B348-B7EFFA06F6B9Q36839790-D8C66904-1914-4899-A2F0-3158E1995E3FQ36852171-2BA2B6A8-CAEA-466E-A739-C8BE6E999971Q36906597-86BFECD5-E6C0-4414-A6F7-2081DC076E34Q36907933-E57C42C3-8A43-4E3E-957C-FC66993B86DBQ36986320-65F6882C-E7C2-4642-9B8E-5DC1398B29F9Q37298667-D26FDC21-3945-437A-8763-AEE9B998E9F3Q37417836-664DF1C9-9F8C-4C68-B7EF-560F47F7DEC8Q37423585-F3036813-9FDF-43BA-947D-4CBDEDD5C168Q37426436-CBBE5720-95F3-4C66-97A9-DEC9D12A7D26Q37515804-2D07683B-B036-49E2-9536-FEBF14958017Q37677940-4EACB764-6EFE-417A-A56D-60FBD7437C66Q37728935-0CE7EEF0-B227-4B9F-99B0-35A3AC410F06Q37825687-9DF1C661-83B0-48DB-93AD-1316CD7917DAQ38286260-B2EA8D0A-7DC6-4C7A-ACEE-6C351A972F56Q38631730-C0FAAAB0-268C-47DA-A884-CA409A5A6E24
P2860
Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.
@ast
Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.
@en
type
label
Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.
@ast
Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.
@en
prefLabel
Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.
@ast
Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.
@en
P1433
P1476
Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting.
@en
P2093
Mark W Dewhirst
P304
P356
10.1158/0008-5472.CAN-06-4744
P407
P577
2007-02-01T00:00:00Z